ArticleJournal of the Chinese Medical Association : JCMA2023
The clinicopathological and genetic differences among gastric cancer patients with no recurrence, early recurrence, and late recurrence after curative surgery.
Article in Journal of the Chinese Medical Association : JCMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- A CT-based deep learning model with biological interpretation for predicting early recurrence after neoadjuvant therapy in gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Prognostic Significance of Albumin-Bilirubin (ALBI) Score in Gastric Cancer Patients Undergoing Curative Resection Followed by Adjuvant Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Development of a risk-stratified follow-up strategy based on early and late recurrence risk factors in locally advanced esophageal squamous cell carcinoma after definitive chemoradiotherapy.Frontiers in oncology · 2026Article
- A challenge for treating patients with extensive-stage small cell lung cancers, particularly for those with liver metastases.Journal of the Chinese Medical Association : JCMA · 2025Article
- Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer : Prognosis Prediction for Resectable GC.Annals of surgical oncology · 2024Article
- One risk factor predicts another risk factor.Journal of the Chinese Medical Association : JCMA · 2023Article
- Can one outcome be used to predict the other outcome?Journal of the Chinese Medical Association : JCMA · 2023Article
- Reply to "Can one outcome be used to predict the other outcome?"Journal of the Chinese Medical Association : JCMA · 2023Article
- Reply to "Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?"Journal of the Chinese Medical Association : JCMA · 2023Article
- Molecular pathology-integrated clinicopathological prognostic factors.Journal of the Chinese Medical Association : JCMA · 2023Article
- Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?Journal of the Chinese Medical Association : JCMA · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo date, few reports have investigated the genetic alterations and clinicopathological features among gastric cancer (GC) patients with no tumor recurrence, early recurrence, and late recurrence following curative surgery.
methodsA total of 473 GC patients undergoing curative surgery were included. The clinicopathological characteristics, patient prognosis, recurrence patterns, and genetic alterations were compared between GC patients with early recurrence and late recurrence.
resultsAmong the 473 GC patients, 119 had early recurrence (<2 years) and 45 had late recurrence (≥2 years). Patients with early recurrence had tumor size larger than 5 cm, fewer superficial-type tumors, more lymphovascular invasion, more advanced pathological T and N categories and Tumor, Node, Metastasis (TNM) stages, and worse 5-year overall survival than patients with late recurrence and no recurrence. For intestinal-type GC, patients with no tumor recurrence had more Helicobacter pylori infection than patients with early recurrence and late recurrence; for diffuse-type GC patients, the frequency of PIK3CA amplification was the highest in early recurrence, followed by late recurrence and no recurrence. GC patients with single-site recurrence had more ARID1A mutations than those with multiple-site recurrence. Multivariate analysis demonstrated that age, tumor recurrence, and pathological N categories were independent prognostic factors.
conclusionPIK3CA amplifications were more common in diffuse-type GC with early recurrence, whereas ARID1A mutations were more common in patients with single-site recurrence. Targeted therapy and immunotherapy might be helpful for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.